Welcome to our dedicated page for ATRECA A news (Ticker: BCEL), a resource for investors and traders seeking the latest updates and insights on ATRECA A stock.
Atreca Inc (NASDAQ: BCEL) is a pioneering biotechnology company dedicated to the development of innovative cancer immunotherapeutics. Leveraging its unique Immune Repertoire Capture™ (IRC™) technology, Atreca has gained unparalleled insight into the human immune response. This advanced platform allows the company to identify unique antibody-target pairs generated by the immune system during an active immune response against tumors.
Atreca's core focus is on developing antibody-drug conjugates (ADCs), a promising class of therapeutics that combines the targeting capabilities of antibodies with potent anti-cancer drugs. The company’s lead program, APN-497444, targets a novel tumor glycan and exemplifies the potential of Atreca’s discovery platform to generate first-in-class oncology treatments.
Recently, Atreca has undergone a significant corporate reorganization aimed at reducing expenses and extending its cash runway. This includes suspending the development of ATRC-101, a promising therapeutic previously advanced into the clinic, and reducing its workforce by approximately 40%. The company is now concentrating its efforts on advancing preclinical ADC candidates, particularly APN-497444, while preserving its core discovery capabilities.
Atreca has also established strategic partnerships to further its mission. Notably, it has licensed MAM01/ATRC-501, a clinical candidate for malaria prevention, to the Bill & Melinda Gates Medical Research Institute. This partnership underscores Atreca’s commitment to leveraging its platform for both oncology and infectious diseases.
The company’s financial condition and strategic decisions, such as the termination of a long-term lease agreement to reduce operating expenses, reflect a careful balance of innovation and fiscal responsibility. Atreca’s leadership, including CEO John Orwin, emphasizes the importance of focusing resources on high-potential projects while exploring strategic alternatives for non-core assets.
For those interested in contributing to Atreca’s groundbreaking work, the company is actively seeking talented individuals. Open positions can be found on their careers page.
Atreca, a clinical-stage biotechnology company, announced positive results from the Phase 1b trial of ATRC-101, revealing a confirmed complete response and partial response in various cancer types. The trial demonstrated a significant link between tumor response and target expression of ATRC-101. Financially, Atreca reported a net loss of $109.3 million for 2021, with $148.1 million in cash at year's end. The company plans to begin participant selection based on target expression soon, expecting more clinical data in 2H22.
Atreca, a clinical-stage biotechnology company (NASDAQ: BCEL), will report its fourth quarter 2021 financial results on March 3, 2022. A conference call for investors, featuring updates on the ATRC-101 clinical program, will occur at 4:30 p.m. EST. The call can be accessed by dialing (800) 373-6606 domestically or (409) 937-8918 internationally, with a conference ID of 5089907. A replay of the audio webcast will be available for 90 days. Atreca focuses on developing antibody-based immunotherapeutics, with its lead candidate ATRC-101 currently in a Phase 1b study.
Atreca, a clinical-stage biotechnology company (NASDAQ: BCEL), announced the presentation of data on broadly neutralizing SARS-CoV-2 antibodies at the Keystone Symposia Conference from January 30 to February 2, 2022. The poster session is scheduled for January 31, showcasing antibodies targeting the Receptor Binding Domain. Out of 209 antibodies screened, 24 showed neutralizing activity, with two antibodies neutralizing all tested variants. These findings highlight the potential for developing therapeutics that effectively target emerging viral variants, vital for COVID-19 treatment.
Atreca, a clinical-stage biotechnology company (NASDAQ: BCEL), announced its participation in several upcoming virtual investor conferences. Notable events include the Cowen’s 5th Annual IO Next Summit and Stifel Nicolaus Healthcare Conference, both on November 15, 2021, and the Evercore ISI 4th Annual HealthCONx Conference on November 30, 2021. Live audio webcasts will be accessible on the company’s website, with archived replays available for 90 days following each presentation. Atreca focuses on developing innovative antibody-based immunotherapeutics targeting oncology.
Atreca, Inc. (NASDAQ: BCEL) announced its third-quarter financial results, reporting a net loss of $27.4 million or $0.74 per share for the period ending September 30, 2021. Cash reserves stood at $152.9 million, providing a runway through mid-2023. The company is advancing its lead program ATRC-101, with ongoing enrollment in its Phase 1b trial and plans to release further data in 2022. Additionally, Atreca entered a licensing agreement with the Bill & Melinda Gates Medical Research Institute for MAM01/ATRC-501, a monoclonal antibody aimed at malaria prevention.
Atreca, Inc. (NASDAQ: BCEL) announces a licensing agreement with the Bill & Melinda Gates Medical Research Institute to develop MAM01/ATRC-501, a monoclonal antibody for malaria prevention. Gates MRI will lead the development, focusing on infant and pediatric populations in malaria-endemic regions, while Atreca retains commercial rights in the U.S., Europe, and parts of Asia. MAM01/ATRC-501 has shown efficacy in animal studies and is based on antibodies generated via vaccination with Mosquirix™. This collaboration aims to address the significant global malaria burden.
Atreca, a clinical-stage biotechnology company (NASDAQ: BCEL), announced two poster presentations at the upcoming SITC 2021 Annual Meeting in Washington, D.C., scheduled for November 10-14, 2021. The first presentation will focus on the Phase 1b study of ATRC-101, a novel tumor-targeting antibody for solid tumors, while the second will examine preclinical results for mATRC-101 in synergy with Doxorubicin. Full abstracts are set to be released on November 9, 2021, with the posters accessible on Atreca’s website after November 12.
Atreca, a clinical-stage biotechnology company (NASDAQ: BCEL), will participate in two upcoming virtual investor conferences: the HC Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021, and the Baird Global Healthcare Conference on September 14-15, 2021. The HC Wainwright presentation will be available on-demand starting September 13 at 7:00 a.m. EDT. Atreca focuses on developing novel therapeutics through its unique discovery platform, with its lead candidate ATRC-101 currently undergoing clinical trials.
Atreca, Inc. (NASDAQ: BCEL) reported its second-quarter financial results for 2021, highlighting the progress in its Phase 1b trial for ATRC-101 aimed at solid tumors. The trial demonstrated that ATRC-101 was well-tolerated, with 40% of participants showing stable disease and some experiencing tumor size reduction. Financially, Atreca ended the quarter with $182.3 million in cash, while reporting a net loss of $26.7 million, equating to a loss per share of $0.72. The company plans further updates on its pipeline and combination studies in 2022.
Atreca, a clinical-stage biotechnology company trading under the symbol BCEL, announced its participation in two upcoming virtual investor conferences. The Wedbush PacGrow Healthcare Conference will take place on August 10, 2021, featuring a panel discussion titled 'Heavenly (anti)Bodies' at 1:10 p.m. EDT. Following this, Atreca will present at the Canaccord Genuity 41st Annual Growth Conference on August 12, 2021, during a fireside chat at 3:00 p.m. EDT. Investors can access a live audio webcast of the Canaccord presentation on Atreca's website.
FAQ
What is the current stock price of ATRECA A (BCEL)?
What is the market cap of ATRECA A (BCEL)?
What is Atreca Inc's primary focus?
What technology does Atreca use for its research?
What is APN-497444?
Why did Atreca suspend the development of ATRC-101?
What partnerships has Atreca established?
What recent corporate actions has Atreca taken?
Who is the CEO of Atreca?
How does Atreca's discovery platform benefit oncology research?
What opportunities are there to work at Atreca?
Where can I find the latest financial results of Atreca?
